Quest Diagnostics has seen a significant boost following a series of innovation, customer wins, and strategic acquisitions. As part of their growth strategy, Quest has made major moves to consolidate the diagnostics market, recently announcing the acquisition of the LifeLabs from OMERS, Outreach Laboratory Services of OhioHealth and certain lab assets from Allina Health. The company also declared a periodic cash dividend. Recent financial moves include the pricing of $1.85 billion of senior notes and Assenagon Asset Management S.A. boosting its stake in the company. Significant inroads in innovation have been made with the groundbreaking report which exposed alarming STI data amongst pregnant women, and the pioneering development with the acquisition of PathAI Diagnostics to advance AI in cancer diagnosis. The company's stocks have been performing exceedingly well, reaching a 52-week high. An increase in earnings has also led the firm to raise its forecast for 2024. Despite stiff competition and mixed results, Quest Diagnostics remains a formidable player in the bio-tech industry.
Quest Diagnostics DGX News Analytics from Mon, 08 Jan 2024 08:00:00 GMT to Sun, 18 Aug 2024 16:17:12 GMT -
Rating 7
- Innovation 8
- Information 7
- Rumor 6
